Goodvalley delivered solid results amid challenging 2020 While the year came off to a good start based on high live pig prices, solid volume growth and strong production efficiency, the global outbreak of COVID-19 put an abrupt end to the positive development. Demand for live pigs and pork products dropped across our markets due to reduced consumption, temporary closures of slaughterhouses and very limited export activities. The significant negative impact on demand and prices was further exacerbated by the effects of an outbreak of African Swine Fever in Germany in the second half of the year where we also saw a sharp increase in feed prices. “2020 was a year of unprecedented challenges and unusual market conditions, and we are proud to report strong operational performance and solid financial results based on our dedicated employees’ extraordinary discipline and work efforts during a difficult period,” says CEO Hans Henrik Pedersen. Highlights • Group revenue decreased by 4% to DKK 1,463 million (2019: DKK 1,526 million), and Adjusted EBITDA came to DKK 316 million (2019: DKK 274 million), corresponding to an Adjusted EBITDA margin of 21.6% (2019: 17.9%). • The Polish segment’s revenue declined to DKK 871 million (2019: DKK 925 million), and Adjusted EBITDA came to DKK 114 million (2019: DKK 112 million)corresponding to an increase in Adjusted EBITDA margin of 13.1% (2019: 12.1%), realised despite lower pig prices and a drop in the meat to feed ratio as the low pig prices were not reflected in the feed price, which was stable. • Ukrainian segment revenue came to DKK 461 million (2019: DKK 429 million), and Adjusted EBITDA increased to DKK 161 million (2019: DKK 113 million) corresponding to an Adjusted EBITDA margin of 34.8% (2019: 26.3%) driven by a significant improvement in our arable production due to a strong focus on crop rotation, despite flooding at the beginning of the year, and a significantly improved pig production efficiency which lifted the number of pigs sold per sow. • Revenue in the Russian business declined to DKK 131 million (2019: DKK 172 million) due to the lower volume and a decrease in the average sales price, and Adjusted EBITDA fell to DKK 40 million (2019: DKK 49 million) corresponding to an Adjusted EBITDA margin of 30.5% (2019: 28.5%), primarily caused by the PRRS outbreak, which impacted volumes produced throughout the year and entailed a sharp decline in the number of pigs sold per sow. OutlookIn 2021, Goodvalley expects to generate revenue of DKK 1,450 - 1,600 million and an Adjusted EBITDA of 230-280 million. The outlook is based on expectations of a relatively stable pig price level compared to the average price in 2020 and good production efficiency. The outlook for 2021 is based on an average market price for live pigs of DKK 11.30 per kilo slaughter pig (2020 reported: DKK 11.19 per kilo slaughter pig) and a feed price of DKK 1.66 per kilo (2020 reported: DKK 1.65 per kilo) in the pig division and the prevailing economic situation in Goodvalley’s markets. The outlook is furthermore based on exchange rates for the Group’s key currencies remaining at the closing rates in December 2020 for the full year. Further information Group CFO, Jakob Brasted + 45 76 52 20 00 email@example.com GOODVALLEY AT A GLANCE Goodvalley is an international producer of high-quality pork products operating in Poland, Ukraine and Russia based on Danish production standards. The company is to a large extent self-sufficient and masters the whole production chain from field to fork, from growing crops for feed, breeding and slaughtering pigs including using the manure in biogas facilities to produce electricity and organic fertilizer for the fields. Goodvalley is certified as a carbon neutral company by German TÜV and operates according to the highest standards in terms of animal welfare, transparency in the production and sustainable production methods. Attachments Goodvalley Annual Report 2020 Goodvalley Sustainability Report 2020
Medvedev rose to a career high third in the ATP rankings on Monday after finishing runner-up to world number one Novak Djokovic at the Australian Open. On Thursday, Nadal pulled out of the Rotterdam event due to a back injury which forced the 20-times Grand Slam winner to skip Spain's ATP Cup matches earlier this month.
Has sleep been evading you? Here are some tips to enjoy a good night's sleep, no medication required.
Kerbside scheme to cut electronic waste could be launched in UK. Government consulting on scheme that would increase obligation on retailers to take back broken items
'Blossom circles' to bloom across England, Wales and Northern Ireland. Project aims to inspire UK equivalent of hanami – the Japanese custom of relishing fleeting sight and scent of blossom
Acts of pettiness delight me – they’re a reminder of the toddler in us all. The pettiest person in the world is Donald Trump. It is the only thing to recommend him
From hands-free shoes to TikTok neighbour-shaming: this week’s fashion trends. What’s hot and what’s not in fashion this week
Art, amulets and cryptokitties: the new frontier of crytocurrencies. ‘Non-fungible tokens’ are unique images, clips or poems traded online for increasingly large sums
Falling sperm counts 'threaten human survival', expert warns. Epidemiologist Shanna Swan says low counts and changes to sexual development could endanger human species
No jab, no job – the moral minefield confronting the UK government. As ministers review the feasibility of Covid vaccine passports, what limits could society fairly put on refusers?
Stockholm, February 26, 2021 – Anoto Group AB (“Anoto” or the “Company”) announces that the Company’s total number of shares and votes has increased by 30,000,000 shares and votes, respectively. The number of shares and votes in Anoto has increased as a result of the directed rights issue resolved by the Company’s board of directors on December 28, 2020, based on an authorization from the Annual General Meeting held on May 18, 2020, and announced through the press release of December 29, 2020, together with the directed rights issue resolved by the board of directors on January 20, 2021, announced through the press release of the same date and approved by the Extraordinary General Meeting held on February 15, 2021. As of February 26, 2021, the total number of shares and votes in Anoto amounts to 215,658,150 shares and votes, respectively. For further information, please contact: Johannes Haglund, Chief of Staff, Anoto Group AB For more information about Anoto, please visit www.anoto.com or email firstname.lastname@example.org Anoto Group AB (publ), Reg.No. 556532-3929, Flaggan 1165, SE-116 74 Stockholm This information is information that Anoto Group AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, on February 26, 2021 at 08:00 CET. About Anoto GroupAnoto is a publicly held Swedish technology company known globally for innovation in the area of information-rich patterns and the optical recognition of those patterns. It is a leader in digital writing and drawing solutions, having historically used its proprietary technology to develop smartpens and the related software. These smartpens enrich the daily lives of millions of people around the world. Anoto currently has three main business lines: Livescribe retail, Enterprise Forms and OEM. Anoto also owns Knowledge AI, a leading AI based education solution company, as its majority-controlled subsidiary. Anoto is traded on the Small Cap list of Nasdaq Stockholm under ANOT. Attachment Change in number of shares and votes_February 2021 (En)
Right now Teladoc Health is the dominant name in virtual healthcare. Are there any internet companies that might dislodge Teladoc from its leadership position?
Acacia Pharma Group plc Issue of Equity on Exercise of Options/Vesting of Performance Share Awards Cambridge, UK and Indianapolis, US – 26 February 2021, 08:00 CET: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that application has been made to Euronext Brussels for the admission of the 24,500 Ordinary Shares of £0.02 each (the “New Ordinary Shares”) to trading on Euronext Brussels ("Admission") to satisfy the exercise of options granted under the Company’s Enterprise Management Incentive Share Option Plan. The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue. Following issue of the New Ordinary Shares, the Company's total issued share capital consists of 99,713,951 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 99,713,951. Contacts Acacia Pharma Group plcMike Bolinder, CEOGary Gemignani, CFO+44 1223 919760 / +1 317 505 1280IR@acaciapharma.com International MediaMark Swallow, Frazer Hall, David DibleCitigate Dewe Rogerson +44 20 7638 email@example.comUS InvestorsLifeSci AdvisorsIrina Koffler+1 firstname.lastname@example.orgMedia in Belgium and the NetherlandsChris Van Raemdonck+32 499 58 55 31 email@example.com Acacia Pharma Group plcThe Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United KingdomCompany number 9759376 www.acaciapharma.com
Sam Barrett is playing the new character.
NEW YORK and LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that an interview with its CEO, Dr Kunwar Shailubhai, will air on The RedChip Money Report on Bloomberg Television on Saturday, February 27, 2021 at 7 p.m. local time across the United States and on the Bloomberg Network in Europe on Sunday, February 28, 2021 at 6 p.m. local time. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in 73M homes and on the Bloomberg Network in Europe in 100M homes at 6 p.m. local time on Sundays. In the exclusive interview, Dr Shailubhai discusses topline data from Tiziana’s COVID-19 trial, its multiple Phase 2 trial launches expected in 2021, and the potential application of Foralumab in a wide range of autoimmune and inflammatory diseases. “The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. About Tiziana Life Sciences Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients. For further enquiries: United Kingdom Investors: Tiziana Life Sciences plc (TLSA) Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379 U.S. Investor Relations Contact: RedChip Companies, Inc.Dave Gentry407firstname.lastname@example.org
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) ("Takeda") today announced that it has entered into an agreement to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited ("Teijin Pharma"), a Tokyo-based pharmaceutical company, for JPY 133.0 billion, subject to customary legal and regulatory closing conditions.
As a result of the ongoing global virus crisis, the revenue, adjusted EBITDA and profit of AS Tallinna Sadam (hereafter: “the Group”) decreased in Q4. Revenue amounted to EUR 25.3 million decreasing by 15.7% in Q4 year-on-year. The adjusted EBITDA of Q4 was EUR 12.1 million (–18.3%) and the profit amounted to EUR 5.7 million (–32.3%). In 2020, the annual revenue was EUR 107.4 million (–17.8%) and adjusted EBITDA amounted to EUR 58.4 million (–21.4%). Despite the pandemic, the profit for 2020 was EUR 28.5 million (–35.8%). Adjusted EBITDA margin decreased by 2.5 percentage points, but the volume of investments increased to EUR 37.1 million (+26%). According to Valdo Kalm, Chairman of the Management Board of Tallinna Sadam, the negative impact of the pandemic on the company's financial results was particularly noticeable in the Passenger harnours segment, but the overall impact of the virus on the Group's finances was smaller than feared and the year ended with a strong profit given the circumstances. „The year 2020 proved that the business strategy with diversified risks and the contribution to the four business directions is justified. In a situation where the business related to passengers decreased by almost half, we are able to meet the expectations of investors and continue with the promised dividend policy, i.e. pay at least 70% of the previous year's profit for dividends," explained Kalm. Kalm says that the large drop in the number of passengers has been compensated by the highest cargo volume of the last five years, the sales revenue of passenger ferries and icebreaker Botnica, which have all remained at levels comparable to 2019. “The resulting stable cash flow and confidence in the recovery of the passenger business have also enabled us to continue investing in passenger services and infrastructure despite the crisis, especially in the Old City Harbour, where we have introduced innovative environmentally friendly solutions such as automatic mooring and on-shore power supply. This year, despite the slump in the passenger segment, several passenger service and real estate development projects in the Old City Harbour will be completed or continued, including the cruise terminal, the front square of the Terminal D and the pedestrian bridge of the Admiralty Canal,” added Kalm. Please also see Valdo Kalm’s video message. The management of Tallinna Sadam will present the financial results of the Group at a webinar on 26 February at 11:00, to attend, please click here. The webinar will be held in English. Key figures (in million EUR): Q4 Q4 +/– 2020 2019 +/– 2020 2019 % % Revenue 25.3 30.0 –15.7 107.4 130.5 –17.8 Adjusted EBITDA 12.1 14.8 –18.3 58.4 74.3 –21.4 Adjusted EBITDA margin 47.9% 49.5% –1.6 54.4% 56.9% –2.5 Operating profit 6.3 9.1 –31.1 35.6 51.7 –31.2 Income tax 0.0 0.0 – –4.9 –5.8 –14.8 Profit for the period 5.7 8.5 –32.3 28.5 44.4 –35.8 Investments 8.2 10.7 –23.0 37.1 29.5 26.0 31.12.2020 31.12.2019 +/– Total assets 628.1 625.5 0.4% Interest bearing debt 211.6 207.8 1.8% Other liabilities 41.1 40.7 1.0% Equity 375.4 377.0 –0.4% Number of shares 263.0 263.0 0.0% Major events in Q4: The impact of the COVID-19 pandemic continuedCompromise with ESTEVE to end legal disputesAppointment of Indrek Randveer as chairman of the Management Board of TS Laevad OÜEnlight Research started covering Tallinna SadamThe supervisory board approved the company strategy for 2021–2025The results of the mapping of the ecological footprint of Tallinna SadamAndo Leppiman was elected chairman of the Tallinna Sadam nomination committeeCompletion of the parking structure of passenger terminal DPast five years’ record cargo volume in 2020 – 21.3 million tons RevenueRevenue for Q4 of 2020 decreased by EUR 4.7 million, i.e. 15.7%, year on year mainly due to decline in passenger volumes. Annually, the revenue decreased in total by 17.8% to EUR 107.4 million. Revenue decreased in all revenue streams, the sharpest in passenger fees (–59%) and vessel dues (–20%). The decline is mainly attributable to the cancellation of the cruise season as well as reduced ferry timetables and a slight decrease in the volumes of general, dry bulk and container cargo. Growth in the volume of liquid bulk cargo had a positive effect on revenue.The revenue of the Passenger harbours segment decreased because the number of passengers declined in connection with COVID-19 related mobility restrictions, which led to the reduction of ferry timetables and the cancellation of the cruise season. The fourth quarter revenue of the Passenger harbours segment decreased to EUR 6.2 million (–41%)Q4 revenue of the Cargo harbours segment grew by EUR 0.2 million (+2.1%) to EUR 10.6 million. Annually, the revenue of the Cargo harbours segment decreased only slightly because cargo throughput grew by 7%. Cargo volume increased primarily due to liquid bulk, but the increase in the volume of liquid bulk with lower charge did not cover the effect of the decrease in the volume of other types of cargo in total cargo charge revenue.The revenue of the Ferry segment decreased mostly during the summer season when the customer (the state) ordered a smaller number of extra trips and did not order an additional ferry to be put in service. Fourth quarter revenue decreased to EUR 6.9 million (–1.7%).The revenue of the segment Other decreased both in Q4 and annually, because of the shorter summer charter period of the icebreaker Botnica due to COVID-19 related restrictions, which disrupted the production operations of the Canadian charterer. The indexation of the ice-breaking and charter fee rates to the inflation index had a slight positive effect on revenue. Revenue for the fourth quarter decreased to EUR 1.6 million (–27%). EBITDAAdjusted EBITDA for Q4 declined by EUR 2.7 million (–18.3%) year on year. The annual adjusted EBITDA decreased to EUR 58.4 million (–21.4%) due to a fall in the Passenger harbours segment. Adjusted EBITDA margin declined from 56.9% to 54.4%. ProfitThe Group’s net profit for 2020 amounted to EUR 28.5 million, EUR 15.9 million less than a year earlier. Net profit for Q4 was EUR 5.7 million (–32.3%). Profit before tax decreased by EUR 16.7 million to EUR 33.4 million (–33.4%) in 2020. Profit before tax for the fourth quarter decreased by EUR 2.7 million, year on year. Income tax expense decreased by EUR 0.9 million due to a smaller dividend distribution (EUR 30.2 million) compared with dividend paid in 2019 (EUR 35.2 million). InvestmentsQ4 capital investments amounted to EUR 8.2 million, capital investments in 2020 totalled EUR 37.1 million, which is 26% more than in the prior year and the past few years’ highest figure. The main investments were again made at the Old City Harbour, where despite the crisis the Group continued to invest in major improvements to the environment and travel conditions. The largest completed projects were the reconstruction of Terminal D and the construction of a nearby multi-storey parking structure. The installation of on-shore power supply systems and auto-mooring equipment for ferries reached the final phase and the construction of a cruise terminal and a footbridge across the canal of the Admiralty Basin was started. The largest works at the Muuga Harbour were related to improving the conditions of ro-ro traffic. Dredging works were carried out in the turning basin and approach canal of the Paldiski South Harbour. The largest projects in the Ferry segment were the installation of battery bank energy solution on the ferry Tõll in order to achieve energy savings and make the ferry more environmentally friendly and scheduled smaller-scale dry dock maintenance of ferries. On the icebreaker Botnica, the second part of the machinery control system was renewed and other technical systems were also upgraded. Interim condensed consolidated statement of financial position: In thousands of euros 31 December 2020 31 December 2019 ASSETS Current assets Cash and cash equivalents 26,679 35,183 Trade and other receivables 10,183 10,614 Inventories 360 408 Non-current assets held for sale 114 142 Total current assets 37,336 46,347 Non-current assets Investments in associates 1,147 1,609 Other long-term receivables 0 294 Property, plant and equipment 587,506 575,267 Intangible assets 2,104 2,015 Total non-current assets 590,757 579,185 Total assets 628,093 625,532 LIABILITIES Current liabilities Loans and borrowings 17,266 16,266 Derivative financial instruments 102 243 Provisions 1,289 1,915 Government grants 1,919 193 Taxes payable 744 893 Trade and other payables 9,149 11,755 Total current liabilities 30,469 31,265 Non-current liabilities Loans and borrowings 194,314 191,580 Government grants 26,145 24,754 Other payables 1,733 915 Total non-current liabilities 222,192 217,249 Total liabilities 252,661 248,514 EQUITY Share capital at par value 263,000 263,000 Share premium 44,478 44,478 Statutory capital reserve 20,262 18,520 Hedge reserve –102 –243 Retained earnings (prior periods) 19,276 6,859 Profit for the period 28,518 44,404 Total equity 375,432 377,018 Total liabilities and equity 628,093 625,532 Interim condensed consolidated statement of profit or loss: In thousands of euros Q4 2020 Q4 2019 2020 2019 Revenue 25,303 30,005 107,358 130,536 Other income 223 229 3,015 1,017 Operating expenses –7,576 –9,212 –30,858 –36,669 Personnel expenses –5,426 –5,740 –19,491 –19,867 Depreciation, amortisation and impairment –6,199 –6,125 –24,094 –23,037 Other expenses –68 –77 –368 –301 Operating profit 6,257 9,080 35,562 51,679 Finance income and costs Finance income 7 13 36 42 Finance costs –410 –463 –1,705 –1,797 Finance costs – net –403 –450 –1,669 –1,755 Share of profit of an associate accounted for under the equity method –130 –173 –462 244 Profit before income tax 5,724 8,457 33,431 50,168 Income tax 0 0 –4,913 –5,764 Profit for the period 5,724 8,457 28,518 44,404 Attributable to owners of the Parent 5,724 8,457 28,518 44,404 Basic and diluted earnings per share (in euros) 0.02 0.03 0.11 0.17 Basic and diluted earnings per share – continuing operations (in euros) 0.02 0.03 0.11 0.17 Interim condensed consolidated statement of cash flows: In thousands of euros 2020 2019 Cash receipts from sale of goods and services 114,378 138,690 Cash receipts related to other income 94 193 Payments to suppliers –43,954 –47,210 Payments to and on behalf of employees –15,713 –16 892 Payments for other expenses –376 –377 Income tax paid on dividends –4,913 –10,985 Cash from operating activities 49,516 63,419 Purchases of property, plant and equipment –35,811 –27,965 Purchases of intangible assets –661 –550 Proceeds from sale of property, plant and equipment 2,863 39 Government grants received 3,561 0 Dividends received 0 204 Interest received 15 28 Cash used in investing activities –30,033 –28,244 Redemption of debt securities –9,000 –9,000 Loans received 20,000 10,000 Repayments of loans received –7,266 –6,766 Dividends paid –30,008 –34,970 Interest paid –1,694 –1,769 Other payments related to financing activities –19 –50 Cash from/used in financing activities –27,987 –42,555 NET CASH FLOW –8,504 –7,380 Cash and cash equivalents at beginning of the period 35,183 42,563 Change in cash and cash equivalents –8,504 –7,380 Cash and cash equivalents at end of the period 26,679 35,183 Tallinna Sadam is one of the largest cargo- and passenger port complexes in the Baltic Sea region, which serves annually 10 million passengers and 20 million tons of cargo in average. In addition to passenger and freight services, Tallinna Sadam group also operates in shipping business via its subsidiaries – OÜ TS Laevad provides ferry services between the Estonian mainland and the largest islands, and OÜ TS Shipping charters its multifunctional vessel Botnica for icebreaking and construction services in Estonia and offshore projects abroad. Tallinna Sadam group is also a shareholder of an associate AS Green Marine, which provides waste management services. According to unaudited financial results, the group’s sales in 2020 totalled EUR 107.4 million, adjusted EBITDA EUR 58.4 million and profit EUR 28.5 million. Additional information: Marju ZirelHead of Investor RelationsTel. +372 5342 6591E-mail: email@example.com Attachments Tallinna Sadam results 12M 2020 ENG Tallinna Sadam Q4 2020 results presentation ENG Tallinna Sadam Financial Results Q4 and 12M 2020 Data
UPM-Kymmene Corporation Stock Exchange Release (Notice to General Meeting) 26 February 2021 at 09:00 EET Notice to the annual general meeting of UPM-Kymmene Corporation Notice is given to the shareholders of UPM-Kymmene Corporation of the Annual General Meeting to be held on Tuesday, 30 March 2021 starting at 14.00 (EEST) in UPM-Kymmene Corporation’s headquarters at Biofore House, Alvar Aallon katu 1, Helsinki, Finland. The Company’s shareholders can participate and exercise their shareholder rights in the Annual General Meeting only by voting in advance and by submitting counterproposals and asking questions in advance in accordance with the instructions given in this notice and otherwise by the Company. It is not possible to attend the meeting in person. In order to prevent the spread of the Covid-19 pandemic, the Annual General Meeting will be held without shareholders’ and their proxy representatives’ presence at the meeting venue. The Board of Directors of the Company has resolved on extraordinary measures for the meeting pursuant to the temporary legislative act (677/2020) approved by the Finnish Parliament on 15 September 2020. This is necessary in order to ensure the health and safety of the shareholders, employees and other stakeholders of the Company as well as to organise the meeting in a predictable way allowing equal means for shareholders to participate while also ensuring compliance with the current restrictions set by the authorities. For these reasons, shareholders and their proxy representatives can participate in the meeting and use shareholder rights only by voting in advance and by submitting counterproposals and asking questions in advance. Further instructions can be found below in this notice in section C “Instructions for the participants of the Annual General Meeting”. The shareholders and the public may follow the meeting through a webcast. Instructions regarding the webcast are available at upm.com/agm2021. Webcast starts on 30 March 2021 at 14.00 (EEST). It is not possible to ask questions or vote through the webcast. Following the webcast without voting in advance or issuing a proxy is not considered as participation in the Annual General Meeting. Shareholders are requested to note that the webcast will be held only if it can be arranged in compliance with all regulatory rules and restrictions imposed by the Finnish authorities due to the Covid-19 pandemic. A. Matters on the agenda of the Annual General Meeting 1. Opening of the meeting 2. Calling the meeting to order Johan Aalto, Attorney-at-law, will act as the Chair of the Annual General Meeting. If Johan Aalto is not able to act as Chair due to a weighty reason, the Board of Directors will nominate a person it deems most suitable to act as Chair. 3. Election of person to scrutinise the minutes and to supervise the counting of votes Henrik Hautamäki, Attorney-at-law, will act as the person to scrutinise the minutes and supervise the counting of votes. If Henrik Hautamäki is unable to act as the person to scrutinise the minutes and supervise the counting of the votes due to a weighty reason, the Board of Directors will nominate a person it deems most suitable to act as a person to scrutinise the minutes and supervise the counting of votes. 4. Recording the legality of the meeting 5. Recording the attendance at the meeting and adoption of the list of votes The shareholders who have voted in advance in accordance with the instructions of this notice and who have the right to attend the meeting pursuant to Chapter 5, Sections 6 and 6a of the Finnish Limited Liability Companies Act will be recorded to have attended the meeting. The list of votes will be adopted according to the information provided by Euroclear Finland Oy. 6. Presentation of the Financial Statements, the Report of the Board of Directors and the Auditor’s Report for the year 2020 Since the Annual General Meeting may only be attended through advance voting, the Financial Statements, the Board of Directors’ Report and the Auditor’s Report, published by the Company on 2 March 2021, are considered to have been presented to the Annual General Meeting. The Financial Statements, the Board of Directors’ Report and the Auditor’s Report are available on the Company’s website at upm.com/agm2021 as of the abovementioned date. 7. Adoption of the Financial Statements 8. Resolution on the use of the profit shown on the balance sheet and the payment of dividend The Board of Directors proposes that a dividend of EUR 1.30 per share be paid based on the balance sheet to be adopted for the financial year ending 31 December 2020. The dividend will be paid to a shareholder who is registered in the Company’s shareholders’ register held by Euroclear Finland Oy on the dividend record date 1 April 2021. The Board of Directors proposes that the dividend be paid on 12 April 2021. 9. Resolution on the discharge of the members of the Board of Directors and the President and CEO from liability 10. Adoption of the Remuneration Report The Board of Directors proposes that the Annual General Meeting adopts the Remuneration Report for the year 2020. Since the Annual General Meeting may only be attended through advance voting, the Remuneration Report for the year 2020, which will be published by a stock exchange release on 2 March 2021 and will be available on the Company’s website at www.upm.com/agm2021 as of 2 March 2021, is considered to have been presented to the Annual General Meeting. 11. Resolution on the remuneration of the members of the Board of Directors The Board of Directors’ Nomination and Governance Committee proposes that the remuneration of the members of the Board of Directors be raised, as it has remained unchanged since 2017 and that the Chair of the Board of Directors be paid an annual base fee of EUR 195,000 (previously EUR 190,000), Deputy Chair of the Board EUR 140,000 (previously EUR 135,000) and other members of the Board EUR 115,000 (previously EUR 110,000). The Nomination and Governance Committee further proposes that the annual committee fees remain unchanged and that the members of the Board of Directors’ committees be paid annual fees as follows: Audit Committee: Chair EUR 35,000 and members EUR 15,000Remuneration Committee: Chair EUR 20,000 and members EUR 10,000Nomination and Governance Committee: Chair EUR 20,000 and members EUR 10,000. The annual base fee is proposed to be paid in Company shares and cash so that approximately 40% will be payable in the Company shares to be purchased on the Board members’ behalf, and the rest in cash. The Company will pay any costs and transfer tax related to the purchase of the Company shares. Shares thus purchased may not be transferred within two years from the purchase date or until the director’s membership in the Board has ended, whichever occurs first. The annual committee fees are proposed to be paid in cash. If the term of a member of the Board of Directors terminates before the Annual General Meeting of 2022, the Board has a right to decide upon potential reclaim of the annual fees as it deems appropriate. In addition, the Board of Directors’ Nomination and Governance Committee proposes that travel and lodging expenses incurred from meetings held elsewhere than in a director’s place of residence will be paid against invoice. 12. Resolution on the number of members of the Board of Directors The Board of Directors’ Nomination and Governance Committee proposes that the number of members of the Board of Directors be resolved to be nine (9) instead of current ten (10). 13. Election of members of the Board of Directors The Board of Directors’ Nomination and Governance Committee proposes that the following incumbent directors be re-elected to the Board: Berndt Brunow, Henrik Ehrnrooth, Emma FitzGerald, Piia-Noora Kauppi, Marjan Oudeman, Martin à Porta, Kim Wahl and Björn Wahlroos. The Nomination and Governance Committee further proposes that Jari Gustafsson be elected as a new director to the Board. The directors will be elected for a one-year term and their term of office will end upon closure of the next Annual General Meeting. All director nominees have given their consent to the election. Ari Puheloinen and Veli-Matti Reinikkala have announced that they are not available for re-election. The new director nominee Jari Gustafsson (born 1958) is a Finnish citizen and holds a Master’s degree in Political Science from the University of Helsinki. Gustafsson has been the Ambassador of Finland to Greece and Albania since 2020. Previously he has worked as the Permanent Secretary of the Ministry of Economic Affairs and Employment, Finland, as the Ambassador of Finland to People’s Republic of China and Mongolia and as the Ambassador of Finland to Japan. He has also been a Board Member at European Bank for Reconstruction and Development, EBRD, UK and the Deputy Director General, Ministry for Foreign Affairs of Finland, Department for External Economic Relations. The Board of Directors has assessed the director nominees’ independence based on the Finnish Corporate Governance Code’s independence criteria and other factors and circumstances to be taken into account in the overall evaluation from both the standpoint of the Company and the nominees. The Board has also taken into account information provided by the nominees. According to the evaluation carried out by the Board, all director nominees are independent of the Company’s significant shareholders as none of the Company shareholders holds 10 percent or more of the Company’s shares or votes attached thereto. In addition, according to the Board’s director-specific overall evaluation, all director nominees are non-executive and independent of the Company including Berndt Brunow and Björn Wahlroos, although they have been, if re-elected, non-executive directors for 10 consecutive years or more. Based on the Board's overall evaluation of these director nominees’ independence, their independence is not compromised due to their long service history, and no other factors or circumstances have been identified that could impair their independence. The biographical details of all director nominees are available at upm.com/agm2021. 14. Resolution on the remuneration of the auditor Based on the proposal prepared by the Audit Committee, the Board of Directors proposes that the remuneration of the Company’s auditor be paid against invoices approved by the Board of Directors’ Audit Committee. 15. Election of the auditor Based on the proposal prepared by the Audit Committee, the Board of Directors proposes that PricewaterhouseCoopers Oy, a firm of authorised public accountants, be re-elected as the Company’s auditor for a term that will continue until the end of the next Annual General Meeting. PricewaterhouseCoopers Oy has notified the Company that Authorised Public Accountant (KHT) Mikko Nieminen would continue as the lead audit partner. Mikko Nieminen has held this position since 4 April 2019. 16. Authorising the Board of Directors to decide on the issuance of shares and special rights entitling to shares The Board of Directors proposes that the Board be authorised to decide on the issuance of new shares, transfer of treasury shares and issuance of special rights entitling to shares as follows: The aggregate maximum number of new shares that may be issued and treasury shares that may be transferred is 25,000,000 including also the number of shares that can be received on the basis of the special rights referred to in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act. The proposed maximum number of shares corresponds to approximately 4.7 per cent of the Company’s registered number of shares at the time of the proposal. The new shares and the special rights entitling to shares may be issued and the treasury shares transferred to the Company's shareholders in proportion to their existing shareholdings in the Company, or in a directed share issue, deviating from the shareholder's pre-emptive subscription right, if there is a weighty financial reason for doing so from the Company’s point of view, such as using the shares as a consideration in potential mergers or acquisitions, to finance investments or other business-related transactions, to develop the Company’s capital structure, or as a part of the Company's incentive plans. The Board of Directors may also decide on a share issue without payment to the Company itself. In addition, the Board may decide to issue special rights referred to in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act, which carry the right to receive, against payment, new shares in the Company or treasury shares in such a manner that the subscription price of the shares is paid in cash or by using the subscriber's receivable to offset the subscription price. The new shares may be issued and the treasury shares transferred either against payment or without payment. The directed share issue may be without payment only if there is an especially weighty financial reason for doing so from the Company’s point of view and taking the interests of the Company’s all shareholders into consideration. The subscription price of the new shares and the amount payable for the treasury shares shall be recorded in the reserve for invested non-restricted equity. The Board shall decide on all other matters related to the issuances and transfers of shares and special rights entitling to shares. The authorisation will be valid for 18 months from the date of the resolution of the Annual General Meeting. If this authorisation is granted, it will revoke the authorisation to decide on the issuance of shares and special rights entitling to shares which was granted to the Board of Directors by the Annual General Meeting on 31 March 2020. 17. Authorising the Board of Directors to decide on the repurchase of the Company’s own shares The Board of Directors proposes that the Board be authorised to decide on the repurchase of the Company’s own shares as follows: By virtue of the authorisation, the Board may decide to repurchase a maximum of 50,000,000 of the Company’s own shares. The proposed maximum number of shares corresponds to approximately 9.4 per cent of the Company’s registered number of shares at the time of the proposal. The authorisation includes also the right to accept the Company’s own shares as a pledge. The Company’s own shares will be repurchased in public trading otherwise than in proportion to the existing shareholdings of the Company’s shareholders at the market price quoted at the time of purchase on the trading places where the Company’s shares or certificates entitling to its shares are traded, using the Company’s non-restricted shareholders’ equity. The purchase price for the shares will be paid according to the applicable rules of the trading places where the shares have been repurchased. The shares will be repurchased to be used as a consideration in potential mergers or acquisitions, to finance investments or other business-related transactions, to develop the Company’s capital structure, or as a part of the Company’s incentive plans, or to be retained by the Company as treasury shares, transferred or cancelled. The Board shall decide on all other matters related to the repurchase of the Company’s own shares. The authorisation will be valid for 18 months from the date of the resolution of the Annual General Meeting. If this authorisation is granted, it will revoke the repurchase authorisation granted to the Board of Directors by the Annual General Meeting on 31 March 2020. 18. Authorising the Board of Directors to decide on charitable contributions The Board of Directors proposes that the Board be authorised to decide on contributions not exceeding a total of EUR 500,000 for charitable or corresponding purposes and that the Board be authorised to decide on the recipients, purposes and other terms and conditions of the contributions. Contributions would be primarily granted under the Company’s Biofore Share and Care programme whose focus areas are reading and learning, engaging with communities, responsible water use and bioinnovations. The authorisation is proposed to be valid until the next Annual General Meeting. 19. Closing of the meeting B. Documents of the Annual General Meeting The proposals for the resolutions on the matters on the agenda of the Annual General Meeting as well as this notice, are available on UPM-Kymmene Corporation’s website at upm.com/agm2021. The Annual Report of UPM-Kymmene Corporation, including the Company’s Financial Statements, the Report of the Board of Directors and the Auditor’s Report, as well as the Remuneration Report for the year 2020 will be available on the above-mentioned website as of 2 March 2021. Copies of these documents and of this notice will be sent to shareholders upon request. The minutes of the Annual General Meeting will be available on the above-mentioned website as of 13 April 2021 at the latest. C. Instructions for the participants of the Annual General Meeting In order to prevent the spread of the Covid-19 pandemic, the meeting will be organised so that the shareholders and their proxy representatives are not allowed to be present at the meeting venue in person. This is necessary especially in order to ensure the health and safety of the Company's shareholders, employees and other stakeholders and compliance with the applicable restrictions set by the authorities. Shareholders and their proxy representatives cannot participate in the meeting through real-time telecommunications, but shareholders and the public may follow webcast from the meeting. The Company’s shareholders and their proxy representatives can participate in the meeting and use shareholder rights only by voting in advance and by submitting counterproposals and asking questions in advance. 1. Shareholders registered in the shareholders’ register Each shareholder, who is registered on 18 March 2021 in the shareholders’ register of the Company maintained by Euroclear Finland Oy, has the right to participate in the Annual General Meeting by voting in advance and by submitting counterproposals and asking questions in advance.A shareholder, whose shares are registered on his/her personal Finnish book-entry account, is registered in the shareholders’ register of the Company. 2. Registration and advance voting service The registration period and advance voting period will commence on 5 March 2021 at 9:00 (EET), when the deadline for delivering counterproposals to be put to a vote has expired. A shareholder, who is registered in the Company’s shareholders’ register and who wishes to participate in the Annual General Meeting by voting in advance, must register for the Annual General Meeting by giving a prior notice of participation and by delivering his/her votes in advance. Both the notice of participation and votes have to be received by the Company by no later than on Tuesday 23 March 2021 at 16:00 (EET). In connection with the registration, requested information such as the name, personal identification number, address and telephone number of the shareholder must be notified. If another representative than the proxy representative nominated by the Company is used, the requested information such as the name and personal identification number must be notified also regarding such proxy representative. The personal data given by the shareholders or the representatives to Euroclear Finland Oy, the Company or the proxy representative nominated by the Company will be used only in connection with the Annual General Meeting and with the processing of related registrations. For further information on how UPM-Kymmene Corporation processes personal data relating to the Annual General Meeting is available at upm.com/agm2021/privacy-statement. Shareholders with a Finnish book-entry account can register and vote in advance on certain matters on the agenda during the period 5 March 2021 at 9:00 (EET) – 23 March 2021 at 16:00 (EET) in the following manners: a) on the Company’s website upm.com/agm2021 Registration requires strong electronic authentication of the shareholder (such as Finnish banking ID). Shareholders that are legal persons must notify their book-entry account number and other required information upon registration. b) by regular mail or e-mailA shareholder may deliver an advance voting form available on the Company’s website upm.com/agm2021 to Euroclear Finland Oy by regular mail to Euroclear Finland Oy, AGM/UPM, P.O. Box 1110, FI-00101 Helsinki, Finland or by e-mail to firstname.lastname@example.org. The completed advance voting form has to be received by Euroclear Finland Oy by no later than on Tuesday 23 March 2021 at 16:00 (EET). The advance voting form will be available on the Company’s website no later than on 5 March 2021. A representative of the shareholder must in connection with delivering the voting form produce a dated proxy document or otherwise in a reliable manner demonstrate his/her right to represent the shareholder at the Annual General Meeting. If a shareholder participates in the Annual General Meeting by delivering votes in advance to Euroclear Finland Oy, the delivery of the votes before the end of the registration and advance voting period shall constitute due registration for the Annual General Meeting, provided that all information required for registration and advance voting is duly provided. The terms and other instructions concerning the electronic voting are available on the Company’s website upm.com/agm2021. 3. Proxy representatives and powers of attorney A shareholder may participate in the Annual General Meeting through a proxy representative. A proxy representative of a shareholder must also vote in advance in the manner described in this notice. A shareholder also has the possibility, if he/she so wishes, to use the Company’s proxy authorisation service and authorise the independent proxy representative nominated by the Company, Henrik Hautamäki, Attorney-at-law, or a person designated by him to represent the shareholder and exercise on his/her behalf the right to vote through the advance voting procedure in accordance with the voting instructions given by the shareholder. The contact information of the independent proxy representative: Henrik Hautamäki, Attorney-at-law, Hannes Snellman Attorneys Ltd, Eteläesplanadi 20, FI-00130 Helsinki, Finland, e-mail: UPMAGM2021@hannessnellman.com. When authorising the independent proxy representative, the shareholder must deliver to him a dated proxy document as well as voting instructions no later than on 22 March 2021, by which time the documents must be received by the proxy representative. A template for the proxy document and voting instructions will be available on the Company’s website upm.com/agm2021 by no later than 5 March 2021 once the deadline for delivering counterproposals to be put to a vote has expired. A proxy representative shall produce a dated proxy document or otherwise in a reliable manner demonstrate his/her right to represent the shareholder at the Annual General Meeting. If a shareholder participates in the Annual General Meeting by means of several proxy representatives representing the shareholder with shares in different securities accounts, the shares in respect of which each proxy representative represents the shareholder shall be identified in connection with the registration for the Annual General Meeting. Delivery of a proxy document and votes in advance to Euroclear Finland Oy before the expiration of the period for the notice of participation constitutes due registration for the Annual General Meeting if the information required for registering for the meeting set out in C.2. above is included in the documents. 4. Holders of nominee registered shares A holder of nominee registered shares has the right to participate in the Annual General Meeting by virtue of such shares, based on which he/she on the record date of the Annual General Meeting, i.e. on 18 March 2021, would be entitled to be registered in the shareholders’ register of the Company held by Euroclear Finland Oy. The right to participate in the Annual General Meeting requires, in addition, that the shareholder on the basis of such shares has been temporarily preregistered in the shareholders’ register held by Euroclear Finland Oy by 10.00 (EET) on 25 March 2021 at the latest. As regards nominee registered shares, this constitutes a due registration for the Annual General Meeting. A holder of nominee registered shares is advised to request without delay necessary instructions regarding the temporary registration in the shareholders’ register of the Company, the issuing of proxy documents and preregistration for the Annual General Meeting from his/her custodian bank. The account management organisation of the custodian bank has to register a holder of nominee registered shares, who wishes to participate in the Annual General Meeting, temporarily in the shareholders’ register of the Company by the time stated above at the latest. In addition, the account management organisation of the custodian bank must see to the voting in advance on behalf of a holder of nominee-registered shares within the registration period applicable to nominee-registered shares. Further information on these matters can also be found on the Company’s website upm.com/agm2021. 5. Other information Shareholders who hold at least one hundredth of all the shares in the Company have a right to make a counterproposal on the agenda items, to be placed for a vote. Such counterproposals are required to be sent to the Company by email to email@example.com no later than by 4 March 2021 at 10.00 (EET). In connection with making a counterproposal, shareholders are required to provide adequate evidence of shareholding. The counterproposal will be placed for a vote subject to the shareholder having the right to participate in the Annual General Meeting and that the shareholder holds at least one hundredth of all shares in the Company on the record date of the Annual General Meeting. Should the counterproposal not be placed for a vote at the meeting, the votes in favour of the proposal will not be taken into account. The Company will on 5 March 2021 publish on its website upm.com/agm2021 the counterproposals, if any, that may be voted on. A shareholder has the right to ask questions referred to in Chapter 5, Section 25 of the Finnish Limited Liability Companies Act with respect to the matters to be considered at the meeting. Such questions must be sent by email to firstname.lastname@example.org no later than 16 March 2021 at 16:00 (EET). As a prerequisite for presenting questions, a shareholder must present sufficient evidence to the Company of his/her shareholdings. Such questions from shareholders, the Company’s management’s answers to them, and any counterproposals that have not been placed for a vote are available on the Company’s website upm.com/agm2021 on 19 March 2021. In connection with asking questions and making counterproposals, shareholders are required to provide adequate evidence of shareholding. Information on the General Meeting required by the Finnish Limited Liability Companies Act and the Finnish Securities Markets Act is available at upm.com/agm2021. Changes in the number of shares held after the record date of the Annual General Meeting shall not have an effect on the right to participate the meeting nor on the number of votes held by a shareholder in the Meeting. On the date of this notice of the Annual General Meeting, the Company has 533,735,699 shares representing the same number of votes. UPM-Kymmene CorporationBoard of Directors UPM, Media Relations Mon-Fri 9:00-16:00 EETtel. +358 40 588 3284 email@example.com UPMWe deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas: UPM Biorefining, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. As the industry leader in responsibility we are committed to the UN Business Ambition for 1.5°C and the science-based targets to mitigate climate change. We employ 18,000 people worldwide and our annual sales are approximately EUR 8.6 billion. Our shares are listed on Nasdaq Helsinki Ltd. UPM Biofore – Beyond fossils. www.upm.com Follow UPM on Twitter | LinkedIn | Facebook | YouTube | Instagram | #UPM #biofore #beyondfossils
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION (ARTICLE 14, 1ST PARAGRAPH, OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE OF MAJOR HOLDINGS) Acacia Pharma Group plc 1. Summary of the notification Cambridge, UK and Indianapolis, US – 26 February 2021, 08:00 CET: Acacia Pharma Group plc has received a transparency notification dated 23 February 2021 indicating that Cosmo Pharmaceuticals N.V now holds, by virtue of the issue of shares on 23 February 2021, 19.66% of the voting rights of the company. Cosmo has therefore crossed the threshold of 20%. 2. Content of notificationThe notification dated 23 February 2021 contains the following information: Reason of the notification – passive crossing of a thresholdNotification by – a parent undertaking or a controlling personPersons subject to the notification requirement – Cosmo Pharmaceuticals N.V. Riverside 2, Sir John Rogerson’s Quay, Dublin 2, IrelandDate on which the threshold is crossed – 23 February 2021Threshold that is crossed – 20%Denominator – 99,689,451Notified details: A) Voting rightsPrevious notificationAfter the transaction # of voting rights# of voting rights% of voting rightsHolders of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securitiesCosmo Pharmaceuticals N.V.0000.00%0.00%Cosmo Technologies Ltd.19,600,09819,600,098019.66%0.00%Subtotal19,600,09819,600,098 19.66% TOTAL19,600,098019.66%0.00% B) Voting rightsAfter the transactionHolders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement TOTAL 00.00% TOTAL (A+B) # of voting rights% of voting rights CALCULATE19,600,09819.66% ·Full chain of controlled undertakings through which the holding is effectively held: Cosmo Technologies Ltd is a 100% subsidiary of Cosmo Pharmaceuticals N.V. Miscellaneous This press release is available on Acacia Pharma Group plc’s website (https://acaciapharma.com/investors/regulatory-announcements)The notification may be found on Acacia Pharma Group plc’s website ((https://acaciapharma.com/investors/regulatory-announcements) Contacts Acacia Pharma Group plcMike Bolinder, CEOGary Gemignani, CFO+44 1223 919760 / +1 317 505 1280IR@acaciapharma.com International MediaMark Swallow, Frazer Hall, David DibleCitigate Dewe Rogerson +44 20 7638 firstname.lastname@example.orgUS InvestorsLifeSci AdvisorsIrina Koffler+1 email@example.comMedia in Belgium and the NetherlandsChris Van Raemdonck+32 499 58 55 31 firstname.lastname@example.org Acacia Pharma Group plcThe Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United KingdomCompany number 9759376 About Acacia Pharma Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address. Acacia Pharma's first product, BARHEMSYS® (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV). BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market. APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy. Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH. www.acaciapharma.com Attachment TR1 BE 24 Feb 2021
Company announcement, Helsinki, 26 February 2021 at 9:00 am (EET) NEXSTIM PLC FINANCIAL STATEMENTS RELEASE 2020 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), today provides its financial statements for the full year 2020 (1 January–31 December 2020) and H2 2020 (1 July-31 December 2020). Highlights, July – December 2020 Continued to minimize the effect of COVID-19 pandemic as well as focusing on generating profitable revenue growth. Considering the difficult business environment, excellent progress with 9 new NBS systems sold, 3 in the US 6 in the EU and rest of the world. Total of 3 new NBT® systems installed to clinics in the US and Europe, across multiple sites, for the treatment of Major Depressive Disorder (MDD) July 1 – December 31, 2020 was the Company’s best reported second half to date when measured by net sales and operating result. The total net sales in the second half was EUR 2.5 million (2019 H2: EUR 2.1 million) and operating result EUR -1.5 million (2019 H2: -3.2 million) NBS net sales grew by 4% in H2 to EUR 1.3 million (2019 H2: EUR 1.2 million) and the NBT net sales grew by 35% in H2 amounting to EUR 1.2 million (2019 H2: EUR 0.9 million) Started two new pilot studies in treating severe depression (Kuopio University Hospital) and therapy resistant, chronic neuropathic pain patients (Helsinki University Hospital) with accelerated iTBS therapy treatment protocols using NBT system. Post-period Highlights Shareholders were invited to the Extraordinary General Meeting (EGM) of the Company to decide on authorizations for the Board of Directors to decide on share issues and issuances of option rights and special rights to shares. The EGM will be held on Monday, March 1, 2021 Business Overview Nexstim is a neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. The Company developed its NBT® device based on its NBS technology platform; commercialisation of the NBT® system is currently Nexstim’s key strategic focus. NBT® Nexstim’s NBT® platform is based on its unique navigated Transcranial Magnetic Stimulation (nTMS) technology which allows for personalized, accurate, reproducible and non-invasive brain stimulation In May 2018, Nexstim launched its Navigated Brain Therapy (NBT®) system in the US for the treatment of MDD following FDA clearance in November 201 MDD affects more than 300 million people worldwide with 20-40% of patients not responding to current treatment options. As a result, MDD is the key focus for Nexstim’s sales and marketing activities for its NBT® system The NBT® system is CE marked for the treatment of depression and chronic pain Two ongoing pilot studies in treating severe depression and therapy resistant, chronic neuropathic pain patients with accelerated iTBS therapy treatment protocols Active commercial installed base of 31 therapy treatment systems across three continents NBS Nexstim’s NBS system is the only CE-marked and FDA-cleared non-invasive solution for pre-surgical mapping of the motor cortex in brain cancer. Clinical data has been generated demonstrating the value of Nexstim’s unique navigation system for pre-surgical mapping with regard to patient outcomes The NBS system allows surgeons to be better prepared and more aggressive with tumor resection, due to their confidence in the location of the motor and speech cortex because of pre-surgical mapping. The non-invasive device has demonstrated a 46% increase in progression free survival in low grade gliomas versus the current gold standard The NBS system has been sold to approximately 180 research universities and leading hospitals across the world CEO Mikko Karvinen’s review Year 2020 has been a time for Nexstim to adjust and learn a new way of doing business under the global health and financial crisis caused by the COVID-19 pandemic. At first, we faced the crisis by safeguarding our valuable cash resources in the form of executing necessary adjustments needed and quick implementation of a savings program. We continued by ensuring that the vast number of both NBS and NBT® customers could continue to operate their systems in a very difficult business environment. Also new ways of digital sales and marketing were successfully implemented to continue our growth path for the full year 2020. I am proud of our Nexstim teamwork under these extreme conditions, and as a sign of our success we achieved the best year so far measured by several financial metrics, including record revenue level. Fortunately, as we have significantly improved the Company's financial performance, we have also continued to safeguard the well-being of our personnel and doing our best in ensuring that our personnel and family members stay as safe as possible. This has been the first year of implementing our newly renewed strategy for the years 2020-2024. Nexstim continues to enable personalised and effective therapies and diagnostics for challenging brain diseases and disorders. Our main strategic focus will stay in the therapeutic indications where we will bring the new accelerated therapy protocols to the core development path of our business. We see that this is possibly a game changer in the field of TMS treatments as we will seek for validation of higher efficacy rates and to show the benefits of a faster treatment process through our pilot studies. The selected therapeutic applications (MDD, severe depression and chronic pain) represent indications where our unique technology already demonstrates recognisable clinical outcome and customer profitability and where possibly in more severe cases also more hospital inpatient treatments are required in the future. We will progress in our science-based development path so that Nexstim’s navigated TMS device will continue to be at the forefront of delivering new treatments for future indications. The NBS business was a significant source of income for our Company in the full year 2020, with net sales growing by 19% to EUR 2.2 million (2019: EUR 1.8 million). The systems were sold especially well in the United States, where, despite the COVID-19 environment, 6 new NBS Systems were successfully sold and delivered during the year 2020. As a result, the Company's total net sales increased by 23 percent during the full year of 2020 to new record level of EUR 4.1 million (2019: EUR 3.3 million). We also ensured the continuity of the NBS service business despite the difficult customer environment and we did not lose any service contract customers as hospital neurosurgeries continued almost unchanged despite the health crisis. During 2021, we will continue to invest in the growth of the NBS business, for example, with recruitment of new sales team members to our US organization. During full year 2020, the NBT business suffered a bit more from the effects of the COVID-19 pandemic. NBT client clinics and hospitals had to somewhat limit therapy treatments locally due to lockdown measures and mobility restrictions, and this slowed down the number of systems and services sold as well as disposable parts delivered, especially to U.S. therapy clinics. We also had to drastically reduce our commercial personnel in our subsidiaries due to the cost saving program, especially in NBT sales, as the short-term effects of the measures taken were necessary to secure our cash balance. Despite these negative effects, the net sales of the NBT business increased by 28 percent during full year 2020 and amounted to EUR 2.0 million (2019: EUR 1.5 million). During full year 2020, we delivered and installed a total of 8 new NBT® Systems - 6 to the U.S. and 2 to Europe and the rest of the world for use in the treatment of MDD. As a result, there were at the end of 2020 a total of 31 NBT® Systems installed worldwide (16 in the U.S. and 15 in Europe and the rest of the world) for the treatment of depression and chronic neuropathic pain. We are confident that by further emphasising the unique navigation capabilities of the NBT® System, we can increase our market share. This is accomplished by clearly differentiating our system from the TMS systems currently on the market that do not have navigation capabilities. In the future, the need for a navigation function is likely to be further emphasised in technology that could treat patients in hospital for severe, treatment-resistant depression (TRD) and possible suicidal ideation. This could potentially open a new TMS treatment market for Nexstim that is separate from the current treatment of patients with MDD. To better understand the ability of Nexstim’s NBT® System to treat patients with accelerated treatment protocols, we launched two new pilot trials in Finland during H2 2020, one for severe depression at Kuopio University Hospital and another for therapy resistant chronic neuropathic pain at Helsinki University Hospital. We are awaiting first results from the severe depression pilot trial soon. As a company, Nexstim wants to be a pioneer in researching and commercialising this new treatment method that could potentially shake the whole TMS industry. In addition to the commercial advancement of NBT® Systems, we also saw continued development in sales, driven by high-margin aftersales products, including revenue from services, support functions, spare parts, and disposables. As the share of NBT® business from the total revenue increases, the share of recurring revenue is likely to increase. Recurring revenue (total sales of the therapy business excluding NBT® System sales) during full year 2020 covered 86 percent of the therapy business revenue. During the full year 2020, Nexstim achieved an average of EUR 71 thousand in therapy revenue per NBT® System. Nexstim's cash and cash equivalents on December 30, 2020 totalled EUR 3.5 million, including the Kreos loan. During full year 2020, we succeeded in reducing the negative cash flow from operating activities to EUR -2.7 million, compared to EUR -6.7 million in 2019, especially through austerity measures and increased gross margin. The Company loans decreased in April 2020 as innovation funding agency Business Finland decided that a total of EUR 0.9 million from the capital and interest of three loans granted for Nexstim’s research and development projects has been settled by debt cancellation. To further finance our business and growth strategy, we raised a total of EUR 2.2 million in new capital in the spring 2020 rights issue. In terms of operational business, 2021 will be our first full year of executing our renewed strategy. This is a year of focused investments into accelerating our sales growth while continuing to focus on securing the service business of our existing NBS and NBT customer base and increasing the utilisation rate of our current installed base. Parallel to all growth measures we will actively keep monitoring the COVID-19 pandemic environment. We also continue our work to increase the number of NBT® Systems installed for use in the treatment of MDD, and we are doing this in line with our renewed strategy, primarily together with valued partners. The focus is particularly on the large U.S. market, but also in a targeted manor in the EU. At the same time, our goal is to continue to raise awareness of our NBT® System in the market. We aim to do this by increasing the number of patients with MDD treated with NBT® systems. As the number of patients increases and research data on pilot trials of new accelerated treatment protocols accumulate, we will be able to gather more clinical data to demonstrate the usefulness of our unique equipment to numerous depressed patients. This information is used to support our marketing and we believe it will increase the rollout of NBT® Systems in key markets in the U.S. and the EU. There are also plans to continue to leverage our strong network of leading KOL’s and patient registry treatment data. In October 2020 we reported the clinical outcomes of the first 108 patients who had completed NBT therapy for treatment of MDD at clinical sites in the U.S. About 42% of the patients completing the treatment achieved clinical remission and 74% obtained a clinical response at the end of treatment. We will continue to collect this valuable patient registry data aiming to collect a patient data registry of over 200 completed treatment sessions of depression patients during year 2021. We also plan to use this patient registry data to publish a series of background papers highlighting the benefits of our NBT® system in the treatment of major depression. Despite we still live in the prolonged COVID-19 pandemic, we eagerly look forward to the year 2021 as the first full year of executing our new strategy. I know that our Nexstim team will work hard to increase shareholder value over the long-term in the form of stronger competitive advantages, faster growth, and better financial results. While again being optimistic about the future, we will closely continue to monitor the development of the COVID-19 pandemic as we operate our business. Key performance indicators EUR in thousands7-12/20206 months7-12/20196 months1-12/202012 months1-12/201912 monthsNet sales2,499.52,130.74,114.03,348.1Personnel expenses-2,134.2-2,634.0-3,731.5-4,713.0Other operating expenses-1,065.6-1,679.3-2,429.3-3,647.5Depreciation and amortisation-177.7-319.3-366.9-524.6Operating profit (loss)-1,496.2-3,155.5-3,332.7-6,517.5Profit/ -Loss for the period-2,952.5-3,117.8-4,121.6-6,782.6Earnings per share (EUR)-0.01-0.07-0.02-0.25Cash flows from operating activities-1,164.1-3,002.5-2,724.7-6,681.5Cash in hand and at banks3,455.84,266.23,455.84,266.2Total equity-1,469.1-740.1-1,469.1-740.1Equity ratio (%)-28.25-8.49-28.25-8.49Number of shares in the end of the period (pcs)436,622,756 62,789,630 436,622,756 62,786,630 Average number of shares during the period (pcs)439,622,756 42,146,358267,693,026 27,611,274 Diluted number of shares in the end of the period (pcs)478,834,792 64,080,578478,834,792 64,080,578 Diluted average number of shares during the period (pcs)479,482,049 54,664,246290,420,292 36,392,323 Future Outlook Based on its business forecast, the Company expects its revenue to continue to grow during year 2021 and a loss for the period is expected for the financial year. Board of Directors’ Proposal on the Dividend Since it was founded, the Company's operations have been unprofitable, and no dividend has been distributed. In the forthcoming years, the Company will focus on financing the growth and the development of its business and the Company will adhere to a very stringent dividend policy, tied to the Company's results and financial standing. The Company does not expect to be able to distribute dividends in the near future. In the event dividends are distributed, all Shares will be entitled to equal dividends.At the end of the financial period of 2020, the distributable assets of the group’s parent company were EUR 12,353,405.03. The Board of Directors proposes that Nexstim Plc should not pay any dividend for the financial period of 2020. Helsinki 26 February 2021 Nexstim PlcBoard of Directors Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO+358 50 326 email@example.com Erik Penser Bank AB (certified adviser)+46 8 463 83 firstname.lastname@example.org Publication of financial information during year 2021 The company will hold two live webinars for media, investors and analysts on Friday 26 February 2021. Mikko Karvinen CEO, and Joonas Juokslahti CFO, will present the financial and operational results followed by a Q&A session. The first live webinar will be in Finnish and it takes place at 1 pm EET. The second live webinar will be in English at 3 pm EET. Webinar details: To attend the webinars, please register via the links below. Registered participants will receive more information to their e-mail. Live Webinar in Finnish on 26 February 2021 at 1 pm (EET): Register here >>> Live Webinar in English on 26 February 2021 at 3 pm (EET): Register here >>> Half-Yearly Report January-June 2021 (H1) will be published on Friday, August 13, 2021 Nexstim Annual Report 2020 (Report of the Board of Directors, the Financial Statements and Consolidated Financial Statements and the Auditor's Report) will be published on company web pages on Friday, March 5, 2020. The Annual General Meeting is tentatively scheduled to be held on Tuesday, April 29, 2020. About Nexstim Plc Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain. In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information please visit www.nexstim.com Attachments Nexstim Plc Financial Statement Release 2020 EN_FINAL Auditors report 2020 Nexstim Oyj _EN 25.2.2021